Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept

摘要: In the last few years, monoclonal antibodies have revolutionized treatment of retinal neovascular diseases. More recently, a different class drugs, fusion proteins, has provided an alternative strategy with pharmacological differences. addition to commercially available aflibercept, two other ziv-aflibercept and conbercept, been studied in antiangiogenic ocular this scenario, critical review currently data regarding proteins ophthalmic diseases may be timely important contribution. Aflibercept, previously known as VEGF Trap Eye, is protein receptors 1 2 for several related angiogenesis. It firmly joined ranibizumab bevacizumab therapeutic option management AMD-, DME- RVO-associated macular edema. Ziv-aflibercept, systemic chemotherapeutic agent approved metastatic colorectal cancer, recently drawn attention because its potential intravitreal administration, since it was not associated ERG-related signs toxicity experimental study human case reports. Conbercept soluble receptor decoy that blocks all isoforms VEGF-A, VEGF-B, VEGF-C, PlGF, which high binding affinity long half-life vitreous. phase three clinical trial shown efficacy safety. This discusses ophthalmology, emphasis on their application